Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Jazz Pharmaceuticals is a dynamic, global biopharmaceutical company focused on transforming the lives of patients by identifying, developing, and commercializing meaningful products that address unmet medical needs. With a diverse portfolio of marketed medicines and a robust pipeline, Jazz is committed to innovation in challenging areas, primarily neuroscience (including sleep medicine and movement disorders) and oncology (including hematologic malignancies and solid tumors). They strive to make a significant difference for patients, their families, and healthcare professionals worldwide.
Serves as the global corporate headquarters, overseeing international operations, strategic decision-making, finance, legal, and corporate governance.
Located in a modern, prominent office complex in Dublin's Ballsbridge area, designed to support a collaborative and innovative global workforce.
Fosters a culture of innovation, patient-centricity, integrity, and collaboration. Employees are driven by a passion for making a meaningful difference in patients' lives.
The Dublin headquarters establishes Jazz Pharmaceuticals as a global entity with a strategic presence in Europe, facilitating international business, access to European markets, talent, and favorable corporate structures.
Jazz Pharmaceuticals operates globally, with key functions including research and development, clinical trial operations, manufacturing and supply chain management, regulatory affairs, medical affairs, commercial sales and marketing, and corporate support functions. Their presence spans North America, Europe, and other international markets, enabling them to serve patients worldwide.
Waterloo Exchange, 4th Floor, Waterloo Road, Ballsbridge
Dublin
Dublin
Ireland
Address: 3170 Chestnut Street, Suite 300, Philadelphia, PA 19104, USA
Key hub for U.S. market access, sales, marketing, medical affairs, and clinical development activities.
Address: 3180 Porter Drive, Palo Alto, CA 94304, USA
Drives innovation and pipeline development through dedicated R&D teams and laboratories.
Address: Monksland, Athlone, Co. Roscommon, Ireland
Ensures global supply chain integrity and product availability, supporting both European and international markets.
Address: Piazza XX Settembre, 2, 22079 Villa Guardia (CO), Italy
Contributes to the global R&D pipeline with specialized expertise in developing medicines derived from cannabis.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Jazz Pharmaceuticals' leadership includes:
Jazz Pharmaceuticals has been backed by several prominent investors over the years, including:
In the past 12 months (May 2023 - May 2024), Jazz Pharmaceuticals has strengthened its European leadership with two key appointments. The company also announced a planned transition for its Chief Financial Officer, with the incumbent set to retire in early 2025 and a successor named.
Discover the tools Jazz Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Jazz Pharmaceuticals primarily uses the 'firstname.lastname@jazzpharma.com' email format for its employees. Variations may exist, but this is the most commonly observed structure.
firstname.lastname@jazzpharma.com
Format
jane.doe@jazzpharma.com
Example
90%
Success rate
Fierce Pharma • May 16, 2024
Jazz Pharmaceuticals and Sumitomo Pharma received FDA approval for Suvecaltamide (Lumryz in US for this indication), a new treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. This drug was developed from a compound originally explored by Johnson & Johnson for depression....more
Jazz Pharmaceuticals • May 8, 2024
Jazz Pharmaceuticals reported its financial results for the first quarter of 2024, highlighting revenue growth driven by key products in neuroscience and oncology, and provided updates on its product pipeline and strategic priorities....more
Jazz Pharmaceuticals • May 2, 2024
The company announced positive top-line results from its Phase 3 clinical trial (sumitomo collaboration) of suvecaltamide (JZP385), an investigational oral therapy for the treatment of narcolepsy in adult patients. The trial met its primary and key secondary endpoints....more
Jazz Pharmaceuticals • February 28, 2024
The U.S. Food and Drug Administration (FDA) granted Priority Review for the Biologics License Application (BLA) for zanidatamab in previously treated HER2-positive metastatic biliary tract cancer (BTC). This marks a significant step for this potential new therapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Jazz Pharmaceuticals, are just a search away.